Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis

Maciej Nowacki _, Margarita Peterson, Tomasz Kloskowski, Eleanor McCabe, Delia Cortes Guiral, Karol Polom, Katarzyna Pietkun, Barbara Zegarska, Marta Pokrywczynska, Tomasz Drewa, Franco Roviello, Edward A. Medina, Samy L. Habib and Wojciech Zegarski

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:78208-78224. https://doi.org/10.18632/oncotarget.20596

Metrics: PDF 1800 views  |   HTML 4174 views  |   ?  


Maciej Nowacki1, Margarita Peterson2, Tomasz Kloskowski3, Eleanor McCabe2, Delia Cortes Guiral4, Karol Polom5,6, Katarzyna Pietkun7, Barbara Zegarska7, Marta Pokrywczynska3, Tomasz Drewa3, Franco Roviello7, Edward A. Medina8, Samy L. Habib9,10 and Wojciech Zegarski1

1Chair of Department of Surgical Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Oncology Centre of Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland

2Department of Plastic and Reconstructive Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA

3Chair of Urology, Department of Regenerative Medicine, Ludwik Rydygier’s Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, ToruÅ„, Poland

4Department of General Surgery (Peritoneal Surface Surgical Oncology), Fundación Jiménez Díaz Hospital, Madrid, Spain

5General Surgery and Surgical Oncology Department, University of Siena, Siena, Italy

6Department of Surgical Oncology, Medical University of Gdansk, Gdansk, Poland

7Chair of Cosmetology and Aesthetic Dermatology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun. Bydgoszcz, Poland

8Department of Pathology, University of Texas Health, San Antonio, TX, USA

9Department of Cell Systems and Anatomy, University of Texas Health Geriatric Research Education, San Antonio, TX, USA

10South Texas Veterans Health Care System, San Antonio, TX, USA

Correspondence to:

Maciej Nowacki, email: [email protected]

Samy L. Habib, email: [email protected]

Keywords: CRS + HIPEC, HIPEC, PIPAC, peritoneal carcinomatosis, nanomedicine

Received: April 21, 2017     Accepted: August 15, 2017     Published: August 31, 2017


The treatment of peritoneal surface malignances has changed considerably over the last thirty years. Unfortunately, the palliative is the only current treatment for peritoneal carcinomatosis (PC). Two primary intraperitoneal chemotherapeutic methods are used. The first is combination of cytoreductive surgery (CRS) and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC), which has become the gold standard for many cases of PC. The second is Pressurized IntraPeritoneal Aerosol Chemotheprapy (PIPAC), which is promising direction to minimally invasive as safedrug delivery. These methods were improved through multicenter studies and clinical trials that yield important insights and solutions. Major method development has been made through nanomedicine, specifically nanoparticles. Here, we are presenting the latest advances of nanoparticles and their application to precision diagnostics and improved treatment strategies for PC. These advances will likely develop both HIPEC and PIPAC methods that used for in vitro and in vivo studies. Several benefits of using nanoparticles will be discussed including: 1) Nanoparticles as drug delivery systems; 2) Nanoparticles and Near Infrred (NIR) Irradiation; 3) use of nanoparticles in perioperative diagnostic and individualized treatment planning; 4) use of nanoparticles as anticancer dressing’s, hydrogels and as active beeds for optimal reccurence prevention; and 5) finally the curent in vitro and in vivo studies and clinical trials of nanoparticles. The current review highlighted use of nanoparticles as novel tools in improving drug delivery to be effective for treatment patients with peritoneal carcinomatosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20596